McKesson (MCK) FY2025 Earnings Quality Report

Grade: A — Strong Financial Health

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Filed 2025-05-09) + Yahoo Finance

Auditor: Deloitte & Touche LLP — Clean opinion (1 critical audit matter: uncertain tax position related to opioid-related claims)

**Fiscal Year**: McKesson's fiscal year ends March 31. FY2025 = April 1, 2024 through March 31, 2025.

One-line verdict: McKesson earns an A grade by clearing seventeen of eighteen checks — the only flag is a watch on cash versus debt (77% coverage), which is typical for a pharmaceutical distributor that runs a working-capital-intensive model. Revenue grew 16.2% to $359.05B, net income rose 10% to $3.29B attributable to McKesson, FCF hit $5.23B, and the M-Score of -2.48 sits comfortably in the safe zone. The distribution model produces a 3.71% gross margin — razor-thin by design — but the cash conversion (CFFO/NI = 1.85) and Debt/EBITDA of 1.4x show the business generates real cash. The negative reported stockholders' equity ($-2.07B) is a direct consequence of buybacks, not operating deterioration. Deloitte's sole critical audit matter is the uncertain tax position related to opioid settlements — a tax judgment, not an earnings quality concern.

The US Pharmaceutical Distribution Giant

From the 10-K: "We are a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable."

McKesson reports in four segments:

U.S. Pharmaceutical — the core segment, which per the 10-K "distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products in the United States. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices."

Prescription Technology Solutions (RxTS) — per the 10-K: "combines automation and our ability to navigate the healthcare ecosystem to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to address patients' medication access, affordability, and adherence challenges."

Medical-Surgical Solutions — distributes "medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies."

International — international distribution operations.

FY2025 Consolidated Results

From the MD&A:

From the MD&A: "Revenues increased for the year ended March 31, 2025 compared to the prior year largely due to market growth in our U.S. Pharmaceutical segment, including higher volumes largely from retail national account customers and growth in specialty pharmaceuticals. Market growth includes growing drug utilization and newly launched products, partially offset by branded to generic drug conversion. This revenue growth was also favorably impacted by higher pharmaceutical distribution volumes in our International segment."

Gross Margin Compression

Gross margin dropped 44bp from 4.15% to 3.71%. From the MD&A: "Gross profit for the years ended March 31, 2025 and 2024 included gains of $444 million and $244 million, respectively, representing our share of antitrust legal settlements. We recognized these amounts within 'Cost of sales' in the Consolidated Statements of Operations within our U.S. Pharmaceutical segment. Gross profit for the years ended March 31, 2025 and 2024 also included a LIFO charge of $82 million and a credit of $157 million, respectively. The LIFO charge in fiscal 2025 compared to a credit in fiscal 2024 was primarily due to higher brand inflation compared to the prior year."

The gross profit bridge is nuanced: $200M more in antitrust settlement benefits, offset by a $239M swing in LIFO accounting (from +$157M credit to -$82M charge). Net of these items, underlying gross margin is relatively stable.

Net income volatility across FY2022-2024 reflects large opioid litigation charges and settlements. FY2025 represents a more normalized baseline.

Cash Flow: Strong Conversion in a Thin-Margin Business

CFFO jumped 41% from $4.31B to $6.08B on 16% revenue growth. FCF of $5.23B is strong — equivalent to 1.47% of revenue, which for a distribution business with sub-4% gross margins is excellent cash throughput.

Negative Stockholders Equity

McKesson's stockholders' equity has been negative for four consecutive years, declining from $(2.27B) to $(2.07B). This is entirely buyback-driven. The business generates substantial recurring FCF and returns it aggressively to shareholders. Net income attributable to McKesson grew 10% in FY2025 while diluted EPS grew 15% — the 5-point gap is the accretive effect of share reduction (diluted shares fell from 134.1M to 128.1M, a 4.5% decline).

The 18-Point Screening

Revenue Quality

All three revenue-quality checks pass cleanly. DSO of just 23 days is among the lowest in healthcare — reflecting distribution's short billing cycle and efficient working capital. AR grew slightly less than revenue. CFFO grew nearly 3x faster than revenue.

Expense Quality

Inventory growth of 8.8% lagged COGS growth of 16.8% — inventory turns improved despite higher sales volume. SG&A at 63.9% of gross profit is typical for distribution, where thin gross margins mean operating expenses consume a large share.

Cash Flow Quality

C4 watch: Cash of $5.69B against total debt of $7.39B = 77% coverage. This sits between the 50% fail threshold and the 100% pass threshold. For a company with $6.08B of annual CFFO and Debt/EBITDA of 1.4x, the coverage is comfortable — the watch is a technical flag rather than a stress signal.

Balance Sheet

Debt/EBITDA of 1.4x is very healthy. The goodwill+intangibles ratio shows as "-554% of equity" in the raw data because equity is negative, which makes the percentage meaningless as a standalone measure. The absolute numbers are $10.0B of goodwill and $1.5B of intangibles totaling $11.5B — manageable relative to the $75.1B total asset base.

M&A Risk

Goodwill+intangibles actually declined 6% YoY — reflecting amortization on intangibles outpacing any new acquisition activity.

Beneish M-Score

Key Risks from Item 1A

1. Legal and regulatory disputes (the first risk section). From the 10-K: "We experience costly and disruptive legal disputes. We are routinely named as a defendant in litigation or regulatory proceedings and other legal disputes, which may include asserted class action litigation... Regulatory proceedings involve allegations such as false claims, healthcare fraud and abuse, and antitrust violations." The 10-K notes: "The outcome of legal disputes is difficult to predict, and outcomes may occur that we believe are not justified by the evidence or existing law."

2. Opioid distribution litigation. From the 10-K: "We experience costly legal disputes, government actions, and adverse publicity regarding our role in distributing controlled substances such as opioids. The Company is a defendant in many litigation matters alleging claims related to the distribution of controlled substances (opioids), as described in Financial Note 17, Commitments and Contingent Liabilities." The 10-K continues: "The plaintiffs in those cases include governmental entities (such as states, provinces, counties, and municipalities) as well as businesses, groups, and individuals. The cases allege violations of controlled substance laws and other laws, and they make common law claims such as negligence and public nuisance."

3. Insurance gaps and uninsured losses. "We experience losses not covered by insurance or indemnification. Our business exposes us to risks that are inherent in the distribution, manufacturing, dispensing, and administration of pharmaceuticals and medical-surgical supplies, the provision of ancillary services, the conduct of our payer businesses, practice support services, and the provision of products that assist clinical decision-making."

4. Healthcare fraud, waste, and abuse regulation. "We are subject to extensive and frequently changing laws relating to healthcare fraud, waste, and abuse."

5. Goodwill and intangible asset impairment risk. From the 10-K: "We might record significant charges from impairment to goodwill, intangibles, and other long-lived assets." Given $11.5B of goodwill and intangibles on the balance sheet, this remains a structural concern.

6. Opioid-related uncertain tax position (the critical audit matter). From Deloitte: "The Company has recorded charges and related tax benefit for opioid-related claims. In order to account for the uncertainty associated with the ultimate realization of the income tax benefit related to opioid-related claims, the Company recorded an uncertain tax position reserve. Tax benefits from uncertain tax positions are recognized when, based upon the technical tax merits, it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes." Deloitte specifically identified this as complex because "there is significant judgment associated with the assessment of the technical tax merits, including the related interpretation of applicable tax laws and regulations."

Altman Z-Score and F-Score

The Z-Score of 0.62 is artificially depressed by the negative stockholders' equity (a Z-Score input). This is not an accurate reflection of distress risk for a company that generates $6.08B of annual operating cash flow and holds investment-grade credit ratings. The Altman model was designed for manufacturers with positive equity; it mis-scores buyback-heavy capital structures.

Summary

Grade: A. Seventeen passing checks, one watch on cash vs debt that reflects working capital management rather than financial stress.

McKesson runs one of the cleanest operational profiles in the healthcare distribution sector: revenue grew 16%, operating cash flow grew 41%, free cash flow hit $5.23B, DSO was just 23 days, inventory turns improved, and Debt/EBITDA is a healthy 1.4x. The M-Score of -2.48 and accruals ratio of -3.7% show no manipulation signals.

The negative stockholders' equity is a deliberate capital structure choice: McKesson has used its free cash flow to buy back shares aggressively (diluted share count fell 4.5% in FY2025), mechanically driving equity below zero. This is the opposite of distress — a company with so much confidence in its recurring cash flows that it prefers to return capital rather than hold cash on the balance sheet. The 77% cash-to-debt coverage watch flag is a technical artifact of this strategy; the actual debt service capacity is fine.

The real risks disclosed in the 10-K are legal and regulatory: opioid distribution litigation remains ongoing, the uncertain tax position related to opioid settlements is Deloitte's sole critical audit matter, and the distribution model carries inherent regulatory exposure. Earnings-quality risk is minimal; legal and tax risk is where management focuses its contingency reserves.

**Disclaimer**: This report is based on McKesson's FY2025 10-K (SEC EDGAR) and public financial data. This is NOT investment advice.

Data: SEC EDGAR 10-K (Filed 2025-05-09) + Yahoo Finance

Auditor: Deloitte & Touche LLP (Unqualified opinion, 1 critical audit matter)